Overview

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Roche-Genentech
Roche/Genentech Inc.
Treatments:
Obinutuzumab